


5'-Methoxynobiletin

Cat. No.:	HY-134602
CAS No.:	6965-36-2
Molecular Formula:	C ₂₂ H ₂₄ O ₉
Molecular Weight:	432.42
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	5'-Methoxynobiletin is a potent and orally active antinociceptive and anti-inflammatory agent. 5'-Methoxynobiletin is a polymethoxyflavone, that can be isolated from <i>A. conyzoides</i> ^{[1][2]} .																												
In Vivo	<p>5'-Methoxynobiletin (5 mg/kg, IP) significantly decreases leukocyte counting, neutrophil influx and protein concentration in the exudate, as well as reduced the levels of several pro-inflammatory mediators^[2].</p> <p>5'-Methoxynobiletin (100 mg/kg, Orally, once) shows anti-nociceptive and anti-inflammatory activity^[2].</p> <p>5'-Methoxynobiletin (10 mg/kg (IV), 50 mg/kg (oral), once) showed a low oral bioavailability in rats, around 8-11%^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td colspan="2">Swiss mice (female)^[2]</td> </tr> <tr> <td>Dosage:</td> <td colspan="2">100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td colspan="2">Orally</td> </tr> <tr> <td>Result:</td> <td colspan="2">Significantly reduced both phases of formalin-induced nociceptive behavior after 15, 30 and 60 min of oral administration, when compared to control groups. In the neurogenic phase, inhibitions of 43±3%, 68±6% and 53±5% of the nociceptive response were observed, while for the inflammatory phase inhibitions were 70±8%, 91±3% and 85±3% after 15, 30 and 60 min of the oral administration of 5'-Methoxynobiletin, respectively.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td colspan="2">Wistar rats (male)^[2]</td> </tr> <tr> <td>Dosage:</td> <td colspan="2">10 mg/kg (IV), 50 mg/kg (oral)</td> </tr> <tr> <td>Administration:</td> <td colspan="2">IV, oral, once (Pharmacokinetic Analysis)</td> </tr> <tr> <td>Result:</td> <td colspan="2">Pharmacokinetic Parameters of 5'-Methoxynobiletin in male Wistar rats^[1].</td> </tr> <tr> <td></td> <td>IV (10 mg/kg)</td> <td>IG (50 mg/kg)</td> </tr> </table>		Animal Model:	Swiss mice (female) ^[2]		Dosage:	100 mg/kg		Administration:	Orally		Result:	Significantly reduced both phases of formalin-induced nociceptive behavior after 15, 30 and 60 min of oral administration, when compared to control groups. In the neurogenic phase, inhibitions of 43±3%, 68±6% and 53±5% of the nociceptive response were observed, while for the inflammatory phase inhibitions were 70±8%, 91±3% and 85±3% after 15, 30 and 60 min of the oral administration of 5'-Methoxynobiletin, respectively.		Animal Model:	Wistar rats (male) ^[2]		Dosage:	10 mg/kg (IV), 50 mg/kg (oral)		Administration:	IV, oral, once (Pharmacokinetic Analysis)		Result:	Pharmacokinetic Parameters of 5'-Methoxynobiletin in male Wistar rats ^[1] .			IV (10 mg/kg)	IG (50 mg/kg)
Animal Model:	Swiss mice (female) ^[2]																												
Dosage:	100 mg/kg																												
Administration:	Orally																												
Result:	Significantly reduced both phases of formalin-induced nociceptive behavior after 15, 30 and 60 min of oral administration, when compared to control groups. In the neurogenic phase, inhibitions of 43±3%, 68±6% and 53±5% of the nociceptive response were observed, while for the inflammatory phase inhibitions were 70±8%, 91±3% and 85±3% after 15, 30 and 60 min of the oral administration of 5'-Methoxynobiletin, respectively.																												
Animal Model:	Wistar rats (male) ^[2]																												
Dosage:	10 mg/kg (IV), 50 mg/kg (oral)																												
Administration:	IV, oral, once (Pharmacokinetic Analysis)																												
Result:	Pharmacokinetic Parameters of 5'-Methoxynobiletin in male Wistar rats ^[1] .																												
	IV (10 mg/kg)	IG (50 mg/kg)																											

λ (h^{-1})	0.55±0.03	0.29±0.2
T_{max} (h)		2.71±0.49
C_{max} (mg/L)		0.62±0.21
$AUC_{0-\infty}$ (mg·h/L)	8.19±4.1	3.65±0.8
$t_{1/2}$ elimination (h)	1.26±0.1	2.31±0.9
CL (L/h.kg)	1.22±0.26	13.68±0.29
Vd, ss (L/kg)	2.24±0.32	47.46±10.10
F (%)		8.67

REFERENCES

- [1]. Faqueti LG, et al. Antinociceptive and anti-inflammatory activities of standardized extract of polymethoxyflavones from *Ageratum conyzoides*. *J Ethnopharmacol.* 2016 Dec 24;194:369-377.
- [2]. Faqueti LG, et al. Preclinical Pharmacokinetic and Pharmacodynamic Investigation of 5'-Methoxynobiletin from *Ageratum conyzoides*: In vivo and In silico Approaches. *Pharm Res.* 2022 Sep;39(9):2135-2145.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA